Role of nephrectomy in metastatic renal cell carcinoma;Place de la néphrectomie dans la prise en charge des cancers du rein métastatiques

Annales d'Urologie

Volumn 40, Issue 5, 2006, Pages 273-279

  Mottet, N ^a  

^a Clinique Mutualiste   (France)

Author keywords

Immunotherapy; Kidney cancer; Nephrectomy; Prognostic factors; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; HEMATURIA; HUMAN; KIDNEY CARCINOMA; LYMPH NODE DISSECTION; METASTASIS; NEPHRECTOMY; PAIN; PROGNOSIS; SHORT SURVEY; KIDNEY TUMOR; PATHOLOGY; REVIEW;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY;

EID: 33749359936     PISSN: 00034401     EISSN: 17683378     Source Type: Journal    
DOI: 10.1016/j.anuro.2006.07.001     Document Type: Short Survey

References (41)

1. Novick A.C., and Campbell S.C. Renal tumor. In: Walsh P.C., Retik A.B., Darracott Vaughan E., and Wein A.J. (Eds). Campbell's Urology (2002), WB Saunders, Philadelphia 2672-2731
2. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., Malhi S., Wood L., Elson P., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23 (2005) 832-841
3. Negrier S., Escudier B., Gomez F., Douillard J.Y., Ravaud A., Chevreau C., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe francais d'immunothérapie. Ann. Oncol. 13 (2002) 1460-1468
4. Zisman A., Pantuck A.J., Wieder J., Chao D.H., Dorey F., Said J.W., et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20 (2002) 4559-4566
5. Patard J.J., Kim H.L., Lam J.S., Dorey F.J., Pantuck A.J., Zisman A., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 22 (2004) 3316-3322
6. Zisman A., Pantuck A.J., Dorey F., Said J.W., Shvarts O., Quintana D., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19 (2001) 1649-1657
7. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17 (1999) 2530-2540
8. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20 (2002) 289-296
9. Leibovich B.C., Chevillle J.C., Lohse C.M., Zincke H., Frank I., Kwon E.D., et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J. Urol. 174 (2005) 1759-1763
10. Elson P.J., Witte R.S., and Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48 (1988) 7310-7313
11. de Forges A., Rey A., Klink M., Ghosn M., Kramar A., and Droz J.P. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin. Surg. Oncol. 4 (1988) 149-154
12. Palmer P.A., Vinke J., Philip T., Negrier S., Atzpodien J., Kirchner H., et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3 (1992) 475-480
13. Fossa S.D., Kramar A., and Droz J.P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer 30A (1994) 1310-1314
14. Lopez Hanninen E., Kirchner H., and Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 155 (1996) 19-25
15. Bennett R.T., Lerner S.E., Taub H.C., Dutcher J.P., and Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol. 154 (1995) 32-34
16. Baird A.D., Woolfenden K.A., Desmond A.D., Fordham M.V., and Parsons K.F. Outcome and survival with nonsurgical management of renal cell carcinoma. BJU Int. 91 (2003) 600-602
17. Wood C.G. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol. Clin. North Am. 30 (2003) 581-588
18. Couillard D.R. deVere White RW. Surgery for renal cell carcinoma. Urol. Clin. North Am. 20 (1993) 263-275
19. Munro N.P., Woodhams S., Nawrocki J.D., Fletcher M.S., and Thomas P.J. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int. 92 (2003) 240-244
20. Freed S.Z., Halperin J.P., and Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J. Urol. 118 (1977) 538-542
21. Marcus S.G., Choyke P.L., Reiter R., Jaffe G.S., Alexander R.B., Linehan W.M., et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol. 150 (1993) 463-466
22. Wagner J.R., Walther M.M., Linehan W.M., White D.E., Rosenberg S.A., and Yang J.C. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J. Urol. 162 (1999) 43-45
23. Chand V.K., Sidloski J., Clamon G., and Hohl R.J. Long-term follow-up in patients with metastatic renal cell cancer not treated with IL-2. Proc. Am. Soc. Clin. Oncol. 23 (2005) 402s [abstract 4597]
24. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210 (1989) 474-485
25. Rackley R., Novick A., Klein E., Bukowski R., McLain D., and Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol. 152 5Pt1 (1994) 1399-1403
26. Fleischmann J.D. Kim BInterleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J. Urol. 145 (1991) 938-941
27. Fallick M.L., McDermott D.F., LaRock D., Long J.P., and Atkins M.B. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol. 158 (1997) 1691-1695
28. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345 (2001) 1655-1659
29. Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R., and European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 358 (2001) 966-970
30. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171 (2004) 1071-1076
31. Leibovich B.C., Han K.R., Bui M.H., Pantuck A.J., Dorey F.J., Figlin R.A., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98 (2003) 2566-2575
32. Pantuck A.J., Zisman A., Dorey F., Chao D.H., Han K.R., Said J., et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97 (2003) 2995-3002
33. Pantuck A.J., Zisman A., Dorey F., Chao D.H., Han K.R., Said J., et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J. Urol. 169 (2003) 2076-2083
34. Phillips C.K., and Taneja S.S. The role of lymphadenectomy in the surgical management of renal cell carcinoma. Urol. Oncol. 22 (2004) 214-224
35. Finelli A., Kaouk J.H., Fergany A.F., Abreu S.C., Novick A.C., and Gill I.S. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int. 94 (2004) 291-294
36. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338 (1998) 1272-1278
37. Pantuck A.J., Zisman A., Chao D., Dorey F., Flanigan R., De Kernion J.B., et al. Survival advantage of interleukine 2 over interferon immunotherapy when combined with cytoreductive nephrectomy based on SWOG 8949-matched population. J. Urol. 167 (2002) 166S
38. Escudier B., Szczylik C., Eisen T., Stadler W.M., Schwartz B., Shan M., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO Annual meeting. J. Clin. Oncol. 23 (2005) 380s [abstract 4510]
39. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Gore M., Desai A., et al. Final findings from a phase-II placebo controlled randomized discontinuation trial (RDT) of sorafenib (BAY-43-9006) in patients with advanced renal cell carcinoma. J. Clin. Oncol. 23 (2005) 388s [abstract 4544]
40. Négrier S., Perol D., Ravaud A., Chevreau C., Bay J.O., Delva R., et al. Do cytokine improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCI quatro trial. J. Clin. Oncol. 23 (2005) 380s [abstract 4511]
41. Mejean A., André M., Doublet J.D., Fendler J.P., de Fromont M., Helenon O., et al. Cancers du rein. Recommandations du comité de cancérologie de l'Association Française d'Urologie. Prog. Urol. 14 suppl4 (2004) 999-1035 (997)